Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Margherita Rimini(Vita-Salute San Raffaele University), Min-Su Kang(Seoul National University Bundang Hospital), Silvia Foti(Vita-Salute San Raffaele University), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Masafumi Ikeda(National Cancer Center Hospital East), Fabian Finkelmeier(Goethe University Frankfurt), Il Hwan Kim(Louisiana State University), Alessandro Parisi(Marche Polytechnic University), Mario Scartozzi(University of Cagliari), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Gian Paolo Spinelli(Sapienza University of Rome), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stephen L. Chan(Chinese University of Hong Kong), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Mario Domenico Rizzato(University of Padua), Hanne Vandeputte(KU Leuven), Monica Niger(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Tonini(Campus Bio Medico University Hospital), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Federico Rossari(Vita-Salute San Raffaele University), Hong Jae Chon(CHA University Bundang Medical Center), Ingrid Garajová(University of Parma), Daniele Lavacchi(University of Florence), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Tomoyuki Satake(National Cancer Center Hospital East), Rita Balsano(Humanitas University), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Changhoon Yoo(Ulsan College), Jin Won Kim(Seoul National University Bundang Hospital), Antonio De Rosa(Istituto Oncologico Veneto), Chiara Pirrone(Ospedale Policlinico San Martino), Silvana Leo(Ospedale Vito Fazzi), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)
Cited by 47
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k